By David Tuller, DrPH While some medical professionals argue that prolonged non-specific symptoms after acute COVID-19 are psychogenic and that “Long COVID” as a presumed clinical entity was concocted by a cabal of queers and feminists, others are getting on with efforts to disseminate more appropriate information to their colleagues. These efforts often involve drawing …
By David Tuller, DrPH A Final Round in Norway Lightning Process supporters got some bad news recently when a Norwegian national research ethics panel rejected a proposed study because it was poorly designed and fraught with conflicts of interest, as I wrote about here. But that wasn’t the end of the drama. Although the ethics …
By David Tuller, DrPH My friend and colleague Steven Lubet is a professor of law at Northwestern University. He and I have collaborated on a number of articles, including a response to Professor Michael Sharpe’s views on so-called “medically unexplained symptoms” in the journal Medical Humanities and a piece on links between ME/CFS and Long …
Trial By Error: Professor Steven Lubet on Misogyny, Homophobia and Long COVID Denialism Read More »
By David Tuller, DrPH Last week, I wrote about the correction made to the “Highlights” section of the paper reporting the long-term follow-up results for the GETSET trial. (The trial was conducted by Professor Peter White, one of the three lead PACE investigators, and colleagues.) I noted that this correction was not indicated or identified–a …
By David Tuller, DrPH A year ago, I wrote a post about how the biopsychosocial ideological brigades had completed a trifecta of major studies that investigated cognitive behavior therapy for a variety of so-called “medically unexplained symptoms” (MUS). As a group, the studies demonstrated the overall ineffectiveness of CBT as a treatment for this category …
By David Tuller, DrPH I have pressed the Journal of Psychosomatic Research to correct a recent paper, “Guided graded exercise self-help for chronic fatigue syndrome: Long term follow up and cost-effectiveness following the GETSET trial.” The senior author is Professor Peter White. Now the journal has published a revised “Highlights” section of the paper that …
